At 11.8% CAGR Preeclampsia Diagnostics Market To Reach US$ 2,780.4 Million By 2028 | Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG

The symptoms of preeclampsia vary, and can be undetected without a doctor’s help. Some women develop this condition without any warning signs, while others experience severe swelling, high blood pressure, and protein in their urine. Other symptoms include excessive swelling in the face or hands, trouble breathing, and decreased urination. Preeclampsia is often discovered during routine prenatal visits, when blood pressure is monitored. An increase in blood pressure at any time during the pregnancy can be a warning sign of a problem. Preeclampsia increases the risk of placental abruption, which can be life-threatening and lead to heavy bleeding.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4606

The Global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8% during the forecast period (2021-2028).

Growing prevalence of preeclampsia is expected to drive the market growth

Growing perinatal and maternal morbidity & mortality rate is driving need for the early diagnosis of preeclampsia worldwide among pregnant women, which is projected to augment the global preeclampsia diagnostics market growth. For instance, according to the Preeclampsia Foundation, over 10 million women globally develop preeclampsia every year, and approximately 2.5 million preterm birth are caused by preeclampsia annually.

New product launches for preeclampsia is driving the market growth during the forecast period

Increasing introduction of new product by key players is projected to augment the market. For instance, in February 2019, Diabetomics, is a global commercial stage medical diagnostics company announced the launch of Lumella, a rapid point-of-care test for Preeclampsia in Hyderabad, India.

Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 212 million infected individuals worldwide as of August 24 2021.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4606

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, key players involved in the global preeclampsia diagnostics market are facing various challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Preeclampsia Diagnostics Market: Restraint

Lack of awareness regarding the preeclampsia disease is expected to restrict market growth. According to a survey conducted by Progenity, Inc. in May 2021, for cause of maternal death reveals pregnant women lack awareness about preeclampsia. Nearly 30% of pregnant women in the United States experience signs and symptoms of possible preeclampsia. Around 5-8% of all pregnancies are complicated by preeclampsia.

Key Players

Key players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.

Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4606

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Preeclampsia Diagnostics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Preeclampsia Diagnostics Industry Impact

Chapter 2 Global Preeclampsia Diagnostics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Preeclampsia Diagnostics (Volume and Value) by Type
2.3 Global Preeclampsia Diagnostics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Preeclampsia Diagnostics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Preeclampsia Diagnostics Market Analysis
Chapter 6 East Asia Preeclampsia Diagnostics Market Analysis
Chapter 7 Europe Preeclampsia Diagnostics Market Analysis
Chapter 8 South Asia Preeclampsia Diagnostics Market Analysis
Chapter 9 Southeast Asia Preeclampsia Diagnostics Market Analysis
Chapter 10 Middle East Preeclampsia Diagnostics Market Analysis
Chapter 11 Africa Preeclampsia Diagnostics Market Analysis
Chapter 12 Oceania Preeclampsia Diagnostics Market Analysis
Chapter 13 South America Preeclampsia Diagnostics Market Analysis
Chapter 14 Company Profiles and Key Figures in Preeclampsia Diagnostics Business
Chapter 15 Global Preeclampsia Diagnostics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology